查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1376144

勃起功能障碍治疗药物市场规模、份额、趋势分析报告：按产品、地区和细分市场分類的趋势，2023-2030 年

Erectile Dysfunction Drugs Market Size, Share & Trends Analysis Report By Product (Viagra, Cialis, Zydena, Levitra, Stendra, Others), By Region (North America, Europe, APAC, Latin America, MEA), And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 79 Pages | 商品交期: 2-10个工作天内

价格

勃起功能障碍治疗药物市场成长与趋势：

Grand View Research, Inc. 的一项新研究显示，到 2030 年，全球勃起功能障碍药物市场预计将达到 47.9 亿美元。

预计2023年至2030年该市场将以8.8%的年复合成长率扩张。勃起功能障碍盛行率的增加预计将有助于市场成长。根据欧洲泌尿系统协会的数据，2020 年欧洲 40-70 岁男性族群中 ED 的总体盛行率约为 52%。根据波士顿大学医学院的数据，大约 22.0% 的 40 多岁男性和 49.0% 的 70 多岁男性患有勃起功能障碍。因此，预计在预测期内，老年人口的增加将增加 ED 的盛行率，并有望为市场创造有利的成长机会。

礼来公司透过礼来患者支持计划 (LPSP) 提供低成本药物来帮助 ED 患者。该计划为加拿大合格的未投保 ED 患者提供经济援助，并且该计划可能需要註册。因此，犀利士品牌版中此类援助计画的存在可能会让低收入患者更负担得起，也可能导致收益增加。此外，公司也采取联盟和伙伴关係等配合措施，在国外市场製造和商业化产品。例如，2022 年 1 月，Petros Pharmaceuticals, Inc. 与全球受託製造厂商(CDMO) 合作，进行阿伐那非锭剂的商业生产。此次合作旨在取代与 Vivas 的现有合约并提供持续的产品供应。

此外，根据国家医学图书馆（2021）的数据，四川海丝古药业有限公司在中国当地的ED 患者中进行了一项评估 Stendra 安全性和有效性的 3 期临床试验。临床试验结果显示，两种给药的 Stendra 100mg 和 200mg 对中国 ED 患者的治疗效果有所改善。这项临床疗效的证明可能会加强 Strenda (Avanafil) 的市场地位。然而，对勃起功能障碍缺乏认识、对治疗感到羞耻、误诊、围绕疾病的社会耻辱、缺乏谨慎等可能会抑制市场成长。根据欧洲泌尿系统协会（EAU）的一项调查，只有18%的西班牙人听说过ED治疗，而68.0%的人相信其有效性。

勃起功能障碍治疗药物市场报告亮点

  • 按产品划分，由于威而钢在全球范围内的供应以及 ED 患者对该产品的认知度不断提高，威而钢部门市场在 2022 年占据了最大的市场占有率。
  • 北美主导勃起功能障碍药物市场，2022 年销售份额为 51.3%。这是由于该地区疾病负担高、医疗基础设施强大以及新治疗产品的快速核准。
  • 预计亚太地区在预测期内将以 10.2% 的年复合成长率增长最快。该地区的成长得益于新产品的进入该地区。

目录

第1章调查方法和范围

第2章执行摘要

第3章勃起功能障碍治疗药物市场变数、趋势与范围

  • 市场体系展望
  • 普及和成长前景图
  • 市场动态
    • 市场驱动因素分析
    • 市场抑制因素分析
  • 勃起功能障碍药物市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第4章勃起功能障碍治疗药物市场：产品评估与趋势分析

  • 勃起功能障碍药物市场：重点
  • 勃起功能障碍药物市场：2022 年和 2030 年产品趋势和市场占有率分析
  • 威而钢
  • 犀利士
  • 齐德纳
  • 莱维特拉
  • 斯滕德拉
  • 其他的

第5章勃起功能障碍治疗药物市场：区域估计和趋势分析

  • 区域展望
  • 按地区分類的勃起功能障碍药物市场：要点
  • 北美洲
    • 2018-2030 年市场估计与预测
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿拉伯聯合大公国
    • 科威特

第6章竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 市场参与企业分类
    • Pfizer, Inc.
    • Eli Lilly and Company
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi
    • Sun Pharmaceutical Industries Ltd.
    • Bayer AG
    • Petros Pharmaceuticals, Inc.
    • VIVUS, Inc.
    • Auxilium Pharmaceuticals
    • Adamed
    • Cipla Inc.
Product Code: 978-1-68038-604-2

Erectile Dysfunction Drugs Market Growth & Trends:

The global erectile dysfunction drugs market size is expected to reach USD 4.79 billion by 2030, according to a new study by Grand View Research, Inc.. The market is expected to expand at a CAGR of 8.8% from 2023 to 2030. The increasing prevalence of erectile dysfunction is expected to contribute to market growth. According to the European Association of Urology, the overall prevalence of ED was found to be around 52% in the European male population aged 40-70 years in 2020. In addition, according to the Boston University School of Medicine, approximately 22.0% of 40 years aged male population and 49.0% by age of 70 years are affected by erectile dysfunction. Thus, the increasing geriatric population is anticipated to increase the prevalence of ED over the forecast period and is expected to create lucrative growth opportunities in the market.

Eli Lilly and Company is supporting ED patients by offering medicine at low cost through Lilly Patient Support Program (LPSP). This program provides financial assistance to eligible ED uninsured patients in Canada who may require registration for this program. Thus, the presence of such supportive programs for a branded version of Cialis may increase the affordability of the lower-income patient population and also aid in generating increased revenue. Moreover, companies have undertaken initiatives such as collaboration and partnership for the manufacturing and commercialization of products in the overseas market. For instance, in January 2022, Petros Pharmaceuticals Inc. partnered with a global Contract Manufacturing Organization (CDMO) for the commercial production of Avanafil tablets. This partnership was formed with an aim to replace the existing agreement with Vivus Inc. and continue product supply.

Furthermore, according to the National Library of Medicine (2021), a phase 3 clinical trial was conducted by Sichuan Haisco Pharmaceutical Co., Ltd. to evaluate the safety and efficacy of Stendra in patients with ED in mainland China. The results of the clinical trial showed improvement in Chinese ED patients after administration of two doses of Stendra 100 mg & 200 mg. Such proven clinical effectiveness may strengthen Strenda's (Avanafil) position in the market. However, lack of awareness about erectile dysfunction, shame about treatment, false-positive beliefs, social stigma pertaining to the disease, and lack of discretion may restrain the market growth. As per the survey conducted by the European Association of Urology (EAU), only 18% of the Spanish population heard about ED treatment, whereas 68.0% of the population believes the treatment benefits.

Erectile Dysfunction Drugs Market Report Highlights:

  • By product, the viagra segment held the largest market share in 2022 due to the worldwide availability of Viagra and increased awareness about the product among ED patients
  • North America dominated the erectile dysfunction drugs market and accounted for a revenue share of 51.3% in 2022, due to the high burden of disease, strong healthcare infrastructure, and rapid approval of new products for treatment in the region.
  • Asia Pacific is expected to advance at the fastest CAGR of 10.2% during the forecast period. The growth of the region is attributable to the entry of new products into the region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Product
    • 1.1.2. Regional scope
    • 1.1.3. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Erectile Dysfunction Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Erectile Dysfunction Drugs Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's Five Forces
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Erectile Dysfunction Drugs Market: Product Estimates & Trend Analysis

  • 4.1. Erectile Dysfunction Drugs Market: Key Takeaways
  • 4.2. Erectile Dysfunction Drugs Market: Product Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Viagra
    • 4.3.1. Viagra market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Cialis
    • 4.4.1. Cialis market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Zydena
    • 4.5.1. Zydena market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Levitra
    • 4.6.1. Levitra market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7. Stendra
    • 4.7.1. Stendra market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Erectile Dysfunction Drugs Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Outlook
  • 5.2. Erectile Dysfunction Drugs Market by Region: Key Takeaways
  • 5.3. North America
    • 5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.3.2. U.S.
      • 5.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.3.3. Canada
      • 5.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.4. Europe
    • 5.4.1. UK
      • 5.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.2. Germany
      • 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.3. France
      • 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.4. Italy
      • 5.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.5. Spain
      • 5.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.6. Sweden
      • 5.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.7. Norway
      • 5.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.8. Denmark
      • 5.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.5. Asia Pacific
    • 5.5.1. Japan
      • 5.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.2. China
      • 5.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.3. India
      • 5.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.4. Australia
      • 5.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.5. Thailand
      • 5.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.6. South Korea
      • 5.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.6. Latin America
    • 5.6.1. Brazil
      • 5.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.6.2. Mexico
      • 5.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.6.3. Argentina
      • 5.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.7. MEA
    • 5.7.1. Saudi Arabia
      • 5.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.2. South Africa
      • 5.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.3. UAE
      • 5.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.4. Kuwait
      • 5.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Market Participant Categorization
    • 6.2.1. Pfizer, Inc.
      • 6.2.1.1. Company overview
      • 6.2.1.2. Financial performance
      • 6.2.1.3. Product benchmarking
      • 6.2.1.4. Strategic initiatives
    • 6.2.2. Eli Lilly and Company
      • 6.2.2.1. Company overview
      • 6.2.2.2. Financial performance
      • 6.2.2.3. Product benchmarking
      • 6.2.2.4. Strategic initiatives
    • 6.2.3. Teva Pharmaceutical Industries Ltd.
      • 6.2.3.1. Company overview
      • 6.2.3.2. Financial performance
      • 6.2.3.3. Product benchmarking
      • 6.2.3.4. Strategic initiatives
    • 6.2.4. Sanofi
      • 6.2.4.1. Company overview
      • 6.2.4.2. Financial performance
      • 6.2.4.3. Product benchmarking
      • 6.2.4.4. Strategic initiatives
    • 6.2.5. Sun Pharmaceutical Industries Ltd.
      • 6.2.5.1. Company overview
      • 6.2.5.2. Financial performance
      • 6.2.5.3. Product benchmarking
      • 6.2.5.4. Strategic initiatives
    • 6.2.6. Bayer AG
      • 6.2.6.1. Company overview
      • 6.2.6.2. Financial performance
      • 6.2.6.3. Product benchmarking
      • 6.2.6.4. Strategic initiatives
    • 6.2.7. Petros Pharmaceuticals, Inc.
      • 6.2.7.1. Company overview
      • 6.2.7.2. Financial performance
      • 6.2.7.3. Product benchmarking
      • 6.2.7.4. Strategic initiatives
    • 6.2.8. VIVUS, Inc.
      • 6.2.8.1. Company overview
      • 6.2.8.2. Financial performance
      • 6.2.8.3. Product benchmarking
      • 6.2.8.4. Strategic initiatives
    • 6.2.9. Auxilium Pharmaceuticals
      • 6.2.9.1. Company overview
      • 6.2.9.2. Financial performance
      • 6.2.9.3. Product benchmarking
      • 6.2.9.4. Strategic initiatives
    • 6.2.10. Adamed
      • 6.2.10.1. Company overview
      • 6.2.10.2. Financial performance
      • 6.2.10.3. Product benchmarking
      • 6.2.10.4. Strategic initiatives
    • 6.2.11. Cipla Inc.
      • 6.2.11.1. Company overview
      • 6.2.11.2. Financial performance
      • 6.2.11.3. Product benchmarking
      • 6.2.11.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 3 North America erectile dysfunction drugs market, by region, 2018 - 2030 (USD Million)
  • Table 4 U.S. erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 5 Canada erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 6 Europe erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 7 Europe erectile dysfunction drugs market, by region, 2018 - 2030 (USD Million)
  • Table 8 Germany erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 9 UK erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 10 France erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 11 Italy erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 12 Spain erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 13 Sweden erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 14 Norway erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 15 Denmark erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 16 Asia Pacific erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 17 Asia Pacific erectile dysfunction drugs market, by region, 2018 - 2030 (USD Million)
  • Table 18 Japan erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 19 China erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 20 India erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 21 Australia erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 22 Thailand erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 23 South Korea erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 24 Latin America erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 25 Latin America erectile dysfunction drugs market, by region, 2018 - 2030 (USD Million)
  • Table 26 Brazil erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 27 Mexico erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 28 Argentina erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 29 Middle East and Africa erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 30 Middle East and Africa erectile dysfunction drugs market, by region, 2018 - 2030 (USD Million)
  • Table 31 South Africa erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 32 Saudi Arabia erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 33 UAE erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 34 Kuwait erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Erectile dysfunction drugs: Market outlook
  • Fig. 9 Erectile dysfunction drugs: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Erectile dysfunction drugs market driver impact
  • Fig. 15 Erectile dysfunction drugs market restraint impact
  • Fig. 16 Erectile dysfunction drugs market strategic initiatives analysis
  • Fig. 17 Erectile dysfunction drugs market: Product movement analysis
  • Fig. 18 Erectile dysfunction drugs market: Product outlook and key takeaways
  • Fig. 19 Viagra market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 20 Cialis market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 21 Zydena market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 22 Levitra market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 23 Stendra market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 24 Others market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 25 Global erectile dysfunction drugs market: Regional movement analysis
  • Fig. 26 Global erectile dysfunction drugs market: Regional outlook and key takeaways
  • Fig. 27 North America market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 28 U.S. market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 29 Canada market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 30 Europe market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 31 UK market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 32 Germany market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 33 France market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 34 Italy market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 35 Spain market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 36 Sweden market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 37 Norway market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 38 Denmark market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 39 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 40 Japan market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 41 China market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 42 India market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 43 Australia market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 44 Thailand market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 45 South Korea market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 46 Latin America market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 47 Brazil market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 48 Mexico market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 49 Argentina market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 50 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 51 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 52 South Africa market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 53 UAE market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 54 Kuwait market estimates and forecasts, 2018 - 2030 (USD million)